Share
News
-
30 April 2009 /Prices and reimbursement
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A08 (antiobesity preparations, excl. diet products).
-
28 April 2009 /Retail and online sale
Tamiflu®: Beware of counterfeits!
As early as Saturdag, the first spam e-mails offering Tamiflu® were circulated, only shortly after the first reports on swine influenza in Mexico had reached the media.
-
16 April 2009 /Side effects and trials
Side effects from Eltroxin® - status April 2009
Recently, the Danish Medicines Agency has recorded an increase in the number of reported side effects from Eltroxin. The increase is observed after GlaxoSmithKline (GSK) has changed the excipients contained in Eltroxin.
-
03 April 2009 /Authorisation and supervision
The Danish Medicines Agency resumes the allocation of time slots for the first half of 2011
Until 16 December 2009, the Danish Medicines Agency accepts time slot requests for the first half of 2011 for DCP procedures with Denmark as Reference Member State (RMS)
-
03 April 2009 /Product information
Withdrawal of the NES-Spacer® from AstraZeneca A/S
AstraZeneca has identified a problem with the NES-Spacer®, which is an inhalation device to be used together with asthma medicine. If a patient assembles the NES-Spacer® incorrectly, the patient cannot inhale the medicine, and the simultaneous use of a face mask prevents the patient from breathing.
